Glaxosmithkline Pharmaceuticals is currently trading at Rs. 2807.00, up by 7.80 points or 0.28% from its previous closing of Rs. 2799.20 on the BSE. The scrip opened at Rs. 2806.45 and has touched a high and low of Rs. 2832.25 and Rs. 2798.65 respectively. So far 357 shares were traded on the counter. The BSE … Read more
Glenmark Pharmaceuticals’ arm — Glenmark Life Sciences is on track to more than double its capacity over the next four years at a cumulative investment of over Rs 600 crore. The capacity expansion is on the back of company’s plan to enter more regulated growth markets like Brazil, Mexico, Russia, Korea, Taiwan and Saudi Arabia. … Read more
The US Food and Drug Administration (USFDA) has completed an inspection at Alembic Pharmaceuticals’ general oral solid formulation facility at Panelav, Gujarat, India. The facility was inspected from October 22, 2018 to October 26, 2018. At the end of the inspection, the US FDA issued a Form 483 with four procedural observations. The company will … Read more
Laurus Labs has transferred the US Food and Drug Administration (USFDA) approved Abbreviated New Drug Application (ANDA) of Tenofovir Disoproxil Fumarate (TDF) to CASI Pharmaceuticals, Inc., a biopharmaceutical company dedicated to the development and delivery of high quality, cost-effective pharmaceutical products and innovative therapeutics to China and other markets. The TDF is prescribed for the … Read more
Alembic Pharmaceuticals has reported results for second quarter ended September 30, 2018. The company has reported over 2 fold jump in its net profit at Rs 251.06 crore for the quarter under review as compared to Rs 122.10 crore for the same quarter in the previous year. Total income of the company increased by 42.60% … Read more
GlaxoSmithKline Pharmaceuticals has reported results for second quarter ended September 30, 2018. The company has reported a fall of 22.67% in its net profit at Rs 100.77 crore for the quarter under review as compared to Rs 130.32 crore for the same quarter in the previous year. Total income from operations of the company marginally … Read more
Alembic Pharmaceuticals is currently trading at Rs. 616.05, up by 7.95 points or 1.31% from its previous closing of Rs. 608.10 on the BSE. The scrip opened at Rs. 619.35 and has touched a high and low of Rs. 621.00 and Rs. 614.00 respectively. So far 992 shares were traded on the counter. The BSE … Read more
